Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage.
CTLs
PD-1
iCIs
nivolumab
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Sep 2020
15 Sep 2020
Historique:
pubmed:
12
6
2020
medline:
27
1
2021
entrez:
12
6
2020
Statut:
ppublish
Résumé
Recently, immune checkpoint inhibitors (iCIs) have been used to treat cancers. Once some of the iCIs for the treatment of hepatocellular carcinoma (HCC) are certified in clinical trials, they are likely be administered to HCC patients with hepatitis C virus (HCV). However, the immunopathogenesis of HCV after the administration of iCIs has not been clarified. We experienced a lung cancer patient with HCV infection treated by nivolumab, programmed cell death 1 (PD-1) antibody. HCV-RNA gradually decreased after the start of nivolumab treatment. However, no increase in transaminase was observed during the decline of HCV-RNA. It was thought that HCV-specific cytotoxic T lymphocytes (CTLs) were activated by iCIs.
Identifiants
pubmed: 32522918
doi: 10.2169/internalmedicine.3726-19
pmc: PMC7578607
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
RNA, Viral
0
Nivolumab
31YO63LBSN
Transaminases
EC 2.6.1.-
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2245-2248Références
Melanoma Res. 2018 Oct;28(5):475-477
pubmed: 29965880
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Virol. 2016 Sep 12;90(19):8934-46
pubmed: 27466420
Nat Commun. 2019 Feb 18;10(1):814
pubmed: 30778080
Viruses. 2018 Nov 17;10(11):
pubmed: 30453612
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
AIDS. 2019 Sep 1;33(11):F13-F19
pubmed: 31259762
Aliment Pharmacol Ther. 2007 Jun 1;25(11):1293-300
pubmed: 17509097
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
J Gastroenterol. 2011 Feb;46(2):232-41
pubmed: 20714907
Case Rep Oncol Med. 2015;2015:737389
pubmed: 26448890
Lancet Oncol. 2016 Nov;17(11):1590-1598
pubmed: 27733243
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
JAMA. 2016 Apr 19;315(15):1600-9
pubmed: 27092830
Cell. 2015 Aug 27;162(5):937
pubmed: 26317459
Cancer. 2017 Jun 1;123(11):1904-1911
pubmed: 28241095
J Clin Oncol. 2017 May 10;35(14):1542-1549
pubmed: 28328302
Nat Rev Immunol. 2005 Mar;5(3):215-29
pubmed: 15738952
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
J Infect Dis. 2009 Mar 1;199(5):726-36
pubmed: 19199548